GOVX · GeoVax Labs, Inc.
$0.75
+0.02 (+2.36%)
At close · Jul 27
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors collectively raise substantial doubt about the Company's ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company's planned operations, but that our plans do not fully alleviate the substantial doubt about the Company's ability to operate as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$2.54M
Shares
3.47M
GeoVax Labs, Inc. Earnings Call Transcripts
Every quarterly earnings call for GeoVax Labs, Inc. (GOVX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼34.4%
$164,962
−$13.74M
'21 Q4
22-03-10
▼26.2%
$81,526
−$2.43M
'22 Q1
22-05-02
▼100%
$
−$2.24M
'22 Q2
22-08-04
▼100%
$
−$3.97M
'22 Q3
22-11-14
▼100%
$
−$5.38M
'22 Q4
23-03-24
▼100%
$
−$4.04M
'23 Q1
23-05-05
·
$
−$5.93M
'23 Q2
23-08-10
·
$
−$8.41M
'23 Q3
23-11-09
·
$
−$7.59M
'23 Q4
24-03-01
·
$
−$5.85M
'24 Q1
24-05-15
·
$300,677
−$5.06M
'24 Q2
24-08-07
·
$2.79M
−$5.82M
'24 Q3
24-11-13
·
$864,415
−$8.26M
'24 Q4
25-03-28
·
$1.64M
−$5.36M
'25 Q1
25-05-01
▲183.5%
$852,282
−$5.37M
'25 Q2
25-07-29
LATEST
▼100%
$
−$6.32M
'25 Q3
25-11-13
Capital Markets Day
Investor event
2026-05-28
Tribe Public’s Webinar Presentation and Q&A Event
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
GeoVax Labs, Inc. Q3 FY2025 Earnings Call
Confident tone
GEO-MVA Mpox/Smallpox vaccine and EMA expedited path
Gedeptin oncology program and KEYNOTE-689
Partnering, collaboration and non-dilutive funding interest
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
GeoVax Labs, Inc. Q2 FY2025 Earnings Call
Confident tone
GEO-MVA mpox/smallpox vaccine
GEO-CM04S1 COVID-19 vaccine for immunocompromised
Gedeptin in head and neck cancer
Revenue
$852,282
▲ 183.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
GeoVax Labs, Inc. Q1 FY2025 Earnings Call
Positive tone
GEO-CM04S1 COVID-19 vaccine for immunocompromised patients
BARDA Project NextGen contract termination
Gedeptin cancer therapy
Revenue
$1.64M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-28
GeoVax Labs, Inc. Q4 FY2024 Earnings Call
Revenue
$864,415*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
GeoVax Labs, Inc. Q3 FY2024 Earnings Call
Confident tone
GEO-CM04S1 COVID-19 Vaccine
BARDA Project NextGen Award
Gedeptin Oncology Program
Revenue
$2.79M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
GeoVax Labs, Inc. Q2 FY2024 Earnings Call
Revenue
$300,677
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
GeoVax Labs, Inc. Q1 FY2024 Earnings Call
Positive tone
CM04S1 COVID-19 vaccine
Gedeptin Phase II head and neck cancer
Immunocompromised patient focus
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
GeoVax Labs, Inc. Q4 FY2023 Earnings Call
Positive tone
Project NextGen / BARDA award
Gedeptin (advanced head and neck cancer)
GEO-CM04S1 COVID-19 vaccine (mRNA booster)
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
GeoVax Labs, Inc. Q3 FY2023 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
GeoVax Labs, Inc. Q2 FY2023 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
GeoVax Labs, Inc. Q1 FY2023 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-24
GeoVax Labs, Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
GeoVax Labs, Inc. Q3 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
GeoVax Labs, Inc. Q2 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-02
GeoVax Labs, Inc. Q1 FY2022 Earnings Call
Revenue
$81,526
▼ 26.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
GeoVax Labs, Inc. Q4 FY2021 Earnings Call
Revenue
$164,962*
▼ 34.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
GeoVax Labs, Inc. Q3 FY2021 Earnings Call
Revenue
$30,414
▼ 92.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
GeoVax Labs, Inc. Q2 FY2021 Earnings Call
Revenue
$79,708
▼ 81.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
GeoVax Labs, Inc. Q1 FY2021 Earnings Call
Revenue
$110,417
▼ 84.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-23
GeoVax Labs, Inc. Q4 FY2020 Earnings Call
Revenue
$251,621*
▼ 6.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
GeoVax Labs, Inc. Q3 FY2020 Earnings Call
Revenue
$415,458
▲ 24.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls